| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci |
NCT05520814: PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial |
|
|
| Active, not recruiting | 2 | 50 | RoW | PD-1 inhibitors, chemoradiotherapy | Sichuan Cancer Hospital and Research Institute | Nasopharyngeal Carcinoma, PD-1 Inhibitors, Chemoradiotherapy | 12/23 | 12/23 | | |
SCALE-2, NCT05424432: Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus |
|
|
| Recruiting | 2 | 63 | RoW | Neoadjuvant Chemotherapy, Neoadjuvant Toripalimab, Short Course Neoadjuvant Radiotherapy | Jiangsu Cancer Institute & Hospital | Locally Advanced Esophageal Carcinoma | 12/23 | 12/24 | | |
NCT04010071: Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors |
|
|
| Recruiting | 2 | 60 | RoW | axitinib plus toripalimab | Peking Union Medical College Hospital, Shanghai Junshi Bioscience Co., Ltd. | Hepatobiliary Neoplasm, Liver Neoplasm, Biliary Tract Neoplasms | 01/24 | 06/24 | | |
GASTO-1071, NCT04844385: Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 124 | RoW | Toripalimab, Paclitaxel-albumin, Nedaplatin, radiation therapy at a total dose 60 Gy, Capecitabine, radiation therapy at a total dose 50 Gy | Sun Yat-sen University | Esophageal Squamous Cell Carcinoma | 12/24 | 12/24 | | |
YH003004, NCT05031494: A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers |
|
|
| Active, not recruiting | 2 | 129 | US, RoW | YH003, Toripalimab, Nab-paclitaxel, Gemcitabine | Eucure (Beijing) Biopharma Co., Ltd | Melanoma, Pancreatic Ductal Adenocarcinoma | 01/24 | 01/24 | | |
NCT05586100: Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study |
|
|
| Recruiting | 2 | 52 | RoW | Toripalimab+cetuximab | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma | 01/24 | 12/26 | | |
NCT06416696: Toripalimab for High-risk Locally Advanced Cervical Cancer |
|
|
| Recruiting | 2 | 130 | RoW | Toripalimab, Radiotherapy, Chemotherapy(cisplatin) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cervical Cancers | 05/26 | 12/26 | | |
NCT03810339: Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab | Sun Yat-sen University | Solid Tumor, Advanced Cancer | 01/24 | 01/24 | | |
NCT06151743: Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 32 | RoW | three cycles (toripalimab + cetuximab + platinum), Toripalimab + Cetuximab + Platinum, Radical surgery, Radiotherapy or chemoradiotherapy | Eye & ENT Hospital of Fudan University | Locally Advanced Hypopharyngeal Carcinoma | 12/24 | 12/26 | | |
NCT05798845: The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 124 | RoW | SBRT+LDRT, Toripalimab, Chemotherapy drug | Shanghai Chest Hospital, Shanghai Junshi Bioscience Co., Ltd. | NSCLC | 12/24 | 12/25 | | |
NCT04172805: Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma |
|
|
| Recruiting | 2 | 70 | RoW | anlotinib and toripalimab, Anlotinib Hydrochloride | Sun Yat-sen University | Sarcoma,Soft Tissue | 03/24 | 05/24 | | |
NCT06081582: Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC |
|
|
| Recruiting | 2 | 33 | RoW | Toripalimab, Drug: Cetuximab, Drug: Cisplatin, Drug: 5-FU | First Affiliated Hospital of Zhejiang University | Squamous Cell Carcinoma of Head and Neck | 03/24 | 11/24 | | |
NCT06279403: Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 20 | NA | Toripalimab, Cytoreductive Nephrectomy, Axitinib | RenJi Hospital | Clear-cell Metastatic Renal Cell Carcinoma, Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy | 03/26 | 03/29 | | |
TORCH-iTNT, NCT06281405: CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 198 | RoW | PD-1 antibody, Toripalimab, Capecitabine, Short-course radiotherapy | Fudan University | Locally Advanced Rectal Cancer, Neoadjuvant Therapy | 06/26 | 12/28 | | |
| Recruiting | 2 | 140 | RoW | S-1, Tegafur,Gimeracil and Oteracil Potassium Capsules, Toripalimab, Toripalimab Injection, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Nanfang Hospital, Southern Medical University, Zhujiang Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, Xiangya Hospital of Central South University, Wuhan University | Locally Advanced Esophageal Squamous Cell Carcinoma | 12/26 | 12/28 | | |
NCT06362317: Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer |
|
|
| Recruiting | 2 | 300 | RoW | Toripalimab, Lenvatinib, Gemox Chemotherapy（Gemox or GC） | Peking Union Medical College Hospital | Biliary Tract Neoplasms Immunotherapy | 03/25 | 03/26 | | |
NCT04884997: A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma |
|
|
| Recruiting | 2 | 90 | RoW | toripalimab, triprizumab, Temozolomide Injection, Temoda | First Affiliated Hospital of Zhejiang University | Malignant Melanoma | 03/24 | 09/24 | | |
| Not yet recruiting | 2 | 40 | RoW | Toripalimab, SBRT, platinum-containing dual drugs | Shanghai Pulmonary Hospital, Shanghai, China | Non-small Lung Cancer | 06/25 | 06/26 | | |
NCT05860335: Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Cisplatin/Nedaplatin, albumin paclitaxel | Chinese PLA General Hospital | Hypopharyngeal Cancer | 06/25 | 06/25 | | |
| Not yet recruiting | 2 | 51 | NA | Toripalimab | Tianjin Medical University Cancer Institute and Hospital | NSCLC | 03/26 | 03/31 | | |
TOPLINE, NCT06269211: Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression |
|
|
| Not yet recruiting | 2 | 29 | RoW | Toripalimab | Ruijin Hospital, Guangdong Provincial People's Hospital | Carcinoma, Non-Small-Cell Lung | 01/27 | 01/30 | | |
NCT04368078: Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 76 | RoW | Toripalimab plus Lenvatinib, JS001 plus E7080 | Peking Union Medical College Hospital, Shanghai Junshi Bioscience Co., Ltd. | Hepatocellular Carcinoma | 04/24 | 04/25 | | |
LungMate-023, NCT06256237: Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial |
|
|
| Recruiting | 2 | 30 | RoW | JS004, tifcemalimab, Toripalimab, surgery, Etoposide, Platinum | Shanghai Pulmonary Hospital, Shanghai, China | Limited Stage Small Cell Lung Cancer | 01/27 | 01/32 | | |
TORCH-E2, NCT06462053: Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer |
|
|
| Recruiting | 2 | 134 | RoW | Short-course radiotherapy, SCRT, PD-1 antibody (Toripalimab), Toripalimab, Long-course radiotherapy, LCRT, Oxaliplatin, Capecitabine, Xeloda | Fudan University | Early Low Rectal Cancer | 04/26 | 03/27 | | |
NCT06283121: A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab | China Medical University, China, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Gastric Cancer, Metastatic | 11/27 | 11/27 | | |
SLOT, NCT05963490: Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 90 | RoW | Regorafenib, Stivarga, Toripalimab, High/low-dose radiotherapy | Fudan University | Microsatellite Stable Metastatic Colorectal Cancer | 04/24 | 04/26 | | |
NCT06389006: To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer |
|
|
| Recruiting | 2 | 79 | RoW | Disitamab Vedotin for Injection, RC48, Toripalimab, JS001, Epirubicin, Cyclophosphamide, CTX | RemeGen Co., Ltd. | Breast Cancer | 06/25 | 12/26 | | |
NCT05385926: Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 34 | RoW | Radiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Metastatic Nasopharyngeal Cancer | 04/24 | 04/24 | | |
| Not yet recruiting | 2 | 30 | NA | Radiotherapy, Intensity-modulated radiotherapy (IMRT), Toripalimab, Immunotherapy | The Central Hospital of Lishui City | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage | 04/24 | 06/26 | | |
NCT05466019: A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ) |
|
|
| Recruiting | 2 | 30 | RoW | Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU) | The First Hospital of Jilin University | PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer | 05/24 | 12/24 | | |
ChiCTR2100045147: Radiotherapy combined with Toripalimab in the treatment of stage I/II extranodal nasal NK/T cell lymphoma with poor response to chemotherapy: a single-arm, multicenter study |
|
|
| Recruiting | 2 | 41 | China | Radiotherapy + Toripalimab | West China Hospital, Sichuan University ; West China Hospital, Sichuan University, Shanghai Junshi Biosciences Co., Ltd；West China Hospital, Sichuan University | NK/T lymphoma | | | | |
NCT06419673: Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer |
|
|
| Active, not recruiting | 2 | 240 | RoW | Serplulimab, Cisplatin, Carboplatin, Brachytherapy and External Beam Radiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cervical Cancer | 05/25 | 05/28 | | |
TORCH-LE, NCT06455124: Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Radiation, PD-1 antibody, Toripalimab, Capecitabine, Xeloda, Oxaliplatin | Fudan University | Rectal Cancer | 06/26 | 12/29 | | |
NCT05861557: Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 23 | RoW | Toripalimab, Stereotactic Body Radiation Therapy (SBRT) | Tianjin Medical University General Hospital, Tianjin Medical University Cancer Institute and Hospital | Locally Advanced Head and Neck Squamous Cell Carcinoma | 05/24 | 05/25 | | |
ChiCTR2000032369: A multicenter, randomized, controlled, phase II trial for comparing radical concurrent chemoradiotherapy with/without Toripalimab (JS001) and consolidated immunotherapy in locally advanced esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | 2 | 159 | China | Toripalimab (JS001) ;Concurrent chemoradiotherapy ;Concurrent chemoradiotherapy | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Not applicable | esophageal squamous cell carcinoma | | | | |
NCT04418648: Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy |
|
|
| Recruiting | 2 | 170 | RoW | Toripalimab | Sun Yat-sen University, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Panyu Central Hospital | Small Cell Lung Cancer Limited Stage | 05/24 | 05/24 | | |
NCT04447326: Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 106 | NA | Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy, JS001, IC＋CCRT | First Affiliated Hospital of Guangxi Medical University, Shandong Cancer Hospital and Institute, Wuhan Union Hospital, China, The Affiliated Hospital Of Guizhou Medical University, Xiangya Hospital of Central South University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fourth Affiliated Hospital of Guangxi Medical University, LiuZhou People's Hospital, Guilin Medical College, Affiliated Hospital of North Sichuan Medical College | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
RC48-C017, NCT05297552: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 40 | RoW | RC48-ADC, JS001 | RemeGen Co., Ltd. | Muscle Invasive Bladder Carcinoma | 06/24 | 02/25 | | |
NCT05162196: The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 57 | NA | SBRT, Toripalimab, Niraparib | Wuhan University | Recurrent Small Cell Lung Cancer | 06/24 | 12/24 | | |
NCT06415318: TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer |
|
|
| Not yet recruiting | 2 | 25 | NA | Paclitaxel + Ifosfamide + Cisplatin & Toripalimab | Sun Yat-sen University | Penile Cancer | 06/27 | 12/27 | | |
NCT06387628: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer |
|
|
| Recruiting | 2 | 74 | RoW | LM-108, Toripalimab, Eribulin, Nab paclitaxel | Fudan University | TNBC - Triple-Negative Breast Cancer | 04/26 | 04/27 | | |
| Recruiting | 2 | 60 | RoW | neoadjuvant anti-PD-1, neoadjuvant anti-PD-1 with LDRT | Shanghai Chest Hospital | Esophageal Cancer | 05/25 | 05/27 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT04211168: Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers |
|
|
| Recruiting | 2 | 44 | RoW | Toripalimab plus Lenvatinib, JS001 plus E7080 | Peking Union Medical College Hospital, Shanghai Junshi Bioscience Co., Ltd. | Advanced Biliary Tract Cancer | 07/24 | 12/24 | | |
| Not yet recruiting | 2 | 80 | NA | Toripalimab+Chemotherapy, Toripalimab+Chemotherapy followed by consolidation toripalimab | Sun Yat-sen University | Lung Cancer, Nonsmall Cell | 07/26 | 07/29 | | |
NCT06323239: SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 148 | RoW | SBRT, Low-dose Radiotherapy (LDRT), Toripalimab, Gemcitabine, Cisplatin, IMRT | Sun Yat-sen University | Nasopharyngeal Carcinoma | 07/26 | 07/28 | | |
ChiCTR2100045190: Chemotherapy combined with anlotinib, toripalimab and stereotactic body radiotherapy for metastatic nasopharyngeal carcinoma: a prospective, multicenter II phase clinical trial |
|
|
| Recruiting | 2 | 32 | China | Gemcitabine plus cisplatin combined with anlotinib, toripalimab and stereotactic body radiotherapy | The First Affiliated Hospital of Guangxi Medical University ; The First Affiliated Hospital of Guangxi Medical University, Apply for corporate scientific research sponsorship | Nasopharyngeal carcinoma | | | | |
ChiCTR2300068977: Phase II single-arm clinical study of teriprizumab combined with low-dose paclitaxel for injection (albumin-bound) in the treatment of advanced gastric cancer that failed first-line treatment and advanced colorectal cancer that failed standard treatment |
|
|
| Recruiting | 2 | 47 | China | Tuoyi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, paclitaxel - Generic mfg. | Sun Yat-sen University Cancer Center | Advanced gastric cancer, advanced colorectal cancer;Oncology | | | | |
NCT05907512: Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma |
|
|
| Recruiting | 2 | 43 | RoW | Endostar, Toripalimab | Fudan University | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | 08/24 | 08/24 | | |
SINCERE, NCT05933980: Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 44 | RoW | Rego+Tori+Cele, Bayer AG, Innovent Biologics | Sun Yat-sen University | Colorectal Cancer, Liver Metastases, MSS | 09/25 | 12/25 | | |
NCT05016973: A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer |
|
|
| Not yet recruiting | 2 | 25 | RoW | RC48-ADC, Disitamab vedotin, Triplizumab | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Bladder Cancer | 09/24 | 10/24 | | |
NCT05803915: Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy |
|
|
| Not yet recruiting | 2 | 57 | RoW | Toripalimab, JS001 | Peking Union Medical College Hospital | Oral Squamous Cell Carcinoma | 09/24 | 03/26 | | |
ChiCTR2000036630: Adjuvant Capecitabine combined with Toripalimab or Capecitabine only in R0 resected Intrahepatic Cholangiocarcinoma: an open randomised, controlled study |
|
|
| Not yet recruiting | 2 | 70 | China | Toripalimab+capecitabine ;capecitabine | The Third Affiliated Hospital of Naval Military Medical University ; The Third Affiliated Hospital of Naval Military Medical University, Sponsors and Collaborators：the Third Affiliated Hospital of Naval Military Medical University | intrahepatic cholangiocarcinoma, ICC | | | | |
NCT05763927: Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT |
|
|
| Recruiting | 2 | 44 | RoW | Fruquintinib, Toripalimab, Short-course radiotherapy, SRT, TME, Total mesorectal excision | West China Hospital | Rectal Cancer | 10/24 | 04/25 | | |
NCT05386888: A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC |
|
|
| Active, not recruiting | 2 | 65 | RoW | GFH018, Toripalimab, Paclitaxel, Carboplatin, Cisplatin, Pemetrexed, Thoracic Radiation Therapy (TRT) | Zhejiang Genfleet Therapeutics Co., Ltd. | NSCLC, Stage III | 10/24 | 01/25 | | |
NCT05813626: Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 89 | RoW | Toripalimab | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 10/24 | 10/27 | | |
TORCH-E, NCT05555888: The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (） |
|
|
| Recruiting | 2 | 34 | RoW | PD-1 antibody, Toripalimab, Capecitabine, Xeloda, Oxaliplatin, Short-course radiotherapy | Fudan University | Early Low Rectal Cancer | 11/24 | 11/25 | | |
NCT05996484: Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma |
|
|
| Not yet recruiting | 2 | 25 | NA | Toripalimab, JS001, Anlotinib hydrochloride, Anlotinib, Albumin paclitaxel, Paclitaxel For Injection (Albumin Bound), Cisplatin, CDDP | Nanfang Hospital, Southern Medical University | Esophageal Carcinoma, Neoadjuvant Therapy | 11/24 | 07/26 | | |
NCT05479045: A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients |
|
|
| Suspended | 2 | 24 | US | NY-ESO-1 Peptide vaccine, Toripalimab-tpzi, LOQTORZI | Georgetown University, United States Department of Defense, Coherus Biosciences, Inc. | Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3 | 11/25 | 11/26 | | |
NCT05173246: JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection, nab-paclitaxel, Paclitaxel for injection (Albumin Bound), Cisplatin, Cisplatin for injection, Carboplatin, Carboplatin for injection | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd. | Esophageal Small Cell Carcinoma | 11/24 | 11/25 | | |
NCT04462965: Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study |
|
|
| Recruiting | 2 | 294 | RoW | Toripalimab, Temozolomide | Beijing Cancer Hospital | Mucosal Melanoma | 11/24 | 06/25 | | |
NCT04992559: A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC |
|
|
| Recruiting | 2 | 41 | RoW | Consolidation Toripalimab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Head and Neck Squamous Cell Carcinomas | 12/24 | 05/27 | | |
TORCH-R, NCT05628038: The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer |
|
|
| Recruiting | 2 | 93 | RoW | PD-1 antibody, Toripalimab, Capecitabine, Xeloda, 5FU, folinic acid, Oxaliplatin, Irinotecan, Raltitrexed, Radiation | Fudan University | Recurrent Rectal Cancer | 12/24 | 12/25 | | |
NCT05994456: Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer |
|
|
| Recruiting | 2 | 24 | RoW | PD-1 inhibitor, Toripalimab | Sun Yat-sen University | Gastric or Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/24 | | |
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC |
|
|
| Withdrawn | 2 | 80 | Europe, RoW | YH001 + Toripalimab | Eucure (Beijing) Biopharma Co., Ltd | HCC, NSCLC Stage IIIB, NSCLC Stage IV | 12/24 | 03/25 | | |
TRANSFORM, NCT04517214: Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 126 | RoW | Toripalimab, JS001, IMRT to the nasopharynx and neck, RT to the nasopharynx and neck, Gemcitabine and Cisplatin Chemotherapy, GP regimen chemotherapy, Adjuvant chemotherapy with Capecitabine, Xeloda | Fudan University, Fudan University Eye and ENT Hospital, Anhui Provincial Hospital, Sir Run Run Shaw Hospital, Hangzhou Cancer Hospital, Ningbo Medical Center Lihuili Hospital, The First People's Hospital of Changzhou, Cancer Hospital of Chinese Academy of Medical Science, Shenzhen Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Shenzhen People's Hospital, First Affiliated Hospital of Xi'anJiaotong Univerisity, Guangzhou Panyu Central Hospital | Nasopharyngeal Carcinoma | 12/24 | 12/26 | | |
ChiCTR2100044622: A single-arm, single-center, phase II exploratory clinical study of PD-1 combined with nedaplatin and docetaxel for preoperative neoadjuvant treatment of head and neck squamous cell carcinoma |
|
|
| Recruiting | 2 | 31 | China | Teriprizumab injection+Nedaplatin+Docetaxel | Guangxi Medical University Cancer Hospital ; Guangxi Medical University Cancer Hospital, Self-funded | Head and neck squamous cell carcinoma | | | | |
INSIGHT, NCT04995120: Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 42 | RoW | chemotherapy TP regimen combined with Toripalimab, Paclitaxel or Nab-Paclitaxel, Cisplatin | Fudan University | Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms | 12/24 | 12/25 | | |
NCT05420597: Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 61 | RoW | Toripalimab, JS001 | Fudan University | Laryngeal Cancer, Hypopharyngeal Cancer | 12/24 | 12/25 | | |
ChiCTR2100046422: A phase II neoadjuvant study of teriprizumab maintenance therapy for locally advanced head and neck squamous cell carcinoma after radical concurrent chemoradiotherapy |
|
|
| Recruiting | 2 | 70 | China | Toripalimab ;Observation and follow-up | Affiliated Hospital of Qingdao University ; Affiliated Hospital of Qingdao University, Affiliated Hospital of Qingdao University | head and neck squamous cell carcinoma | | | | |
NCT05800340: Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, Nab paclitaxel, Pemetrexed, Carboplatin | Guangdong Provincial People's Hospital, Shanghai Junshi Bioscience Co., Ltd. | Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation, MET Amplification, MET Exon 14 Skipping Mutation | 12/24 | 12/26 | | |
NCT05827770: The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma |
|
|
| Not yet recruiting | 2 | 20 | RoW | Toripalimab combined with Temozolomide | Yong Chen | Melanoma Stage III | 12/24 | 06/25 | | |
BCIRT-01, NCT05975307: Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation |
|
|
| Recruiting | 2 | 64 | RoW | Toripalimab, JS001, Gemcitabine, Cisplatin, Carboplatin, Intensity-modulated radiation therapy | Sun Yat-sen University | Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy | 12/24 | 12/29 | | |
ChiCTR2100042794: A prospective phase II clinical study of radiotherapy combined with teriprizumab in the treatment of elderly locally advanced nasopharyngeal carcinoma |
|
|
| Recruiting | 2 | 71 | China | Radiotherapy+Treprizumab | Medical Ethics Committee of Jiangxi Cancer Hospital ; Jiangxi Cancer Hospital, self-raised | Nasopharyngeal carcinoma | | | | |
NCT05760053: Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma |
|
|
| Recruiting | 2 | 33 | RoW | EP/EC+PD-1, Etoposide, Cisplatin or Carboplatin, plus Toripalimab | Sun Yat-sen University | Toripalimab, First-line Treatment | 02/25 | 02/26 | | |
NCT05715931: Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, Trastuzumab, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) | Yu jiren | Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer | 03/25 | 03/28 | | |
ChiCTR2200063242: Prospective single-arm phase II clinical study of fruquintinib combined with toripalimab and SRT in neoadjuvant therapy for locally advanced rectal cancer |
|
|
| Not yet recruiting | 2 | 44 | | Fruquintinib + toripolimab + CRT | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Hutchison Whampoa Pharmaceutical (Shanghai) Co., LTD. | Rectal Cancer | | | | |
TORAN, ChiCTR2100054901: A phase II trial of anlotinib and toripalimab as maintenance therapy in patients with advanced soft tissue sarcoma after anthracycline-based chemotherapy |
|
|
| Recruiting | 2 | 50 | China | Anlotinib + Toripalimab | West China Hospital, Sichuan University ; West China Hospital, Sichuan University, West China Hospital, Sichuan University; Shanghai Junshi Biosciences Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft tissue sarcoma | | | | |
NCT05842018: Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors) |
|
|
| Not yet recruiting | 2 | 30 | NA | Toripalimab, Anlotinib and Chemotherapy, JS001 | Tianjin Medical University Cancer Institute and Hospital | Non Small Cell Lung Cancer Recurrent | 05/25 | 11/25 | | |
| Recruiting | 2 | 61 | RoW | Surufatinib, Toripalimab, chemotherapy | Zhejiang University | Colorectal Cancer | 06/25 | 06/25 | | |
NCT06080854: AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 108 | RoW | Toripalimab, Gemcitabine, Nab paclitaxel, SBRT | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, Fudan University, Shanghai Changzheng Hospital, The First Affiliated Hospital of Soochow University, Xuzhou Central Hospital | Pancreatic Carcinoma | 06/25 | 06/26 | | |
ChiCTR2000033460: A phase II clinical study of sequential Hypofractionated IMRT combined with toripalimab for Unresectable Stage III Non-Small-Cell Lung Cancer |
|
|
| Recruiting | 2 | 63 | China | sequential Hypofractionated IMRT combined with Toripalimab | Jiangsu Cancer Hospital ; Jiangsu Cancer Hospital, Self-financing | Non-Small-Cell Lung Cancer | | | | |
ChiCTR2000034375: TIP (paclitaxel + ifosfamide + cisplatin) Combined with Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer |
|
|
| Not yet recruiting | 2 | 29 | | TIP (paclitaxel + ifosfamide + cisplatin)+Nimotuzumab+Triprilimab | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Self-financing | Penile Caner | | | | |
ChiCTR2300074672: Efficacy and safety of Toripalimab combined with AP-induced chemotherapy followed by concurrent chemoradiotherapy and Toripalimab-maintenance therapy sequentially in patients with non-metastatic IVB hypopharyngeal cancer : A open-lable, single-arm ,phase II clinical study |
|
|
| Recruiting | 2 | 30 | | Terriprizumab injection combined with AP induction chemotherapy, sequential concurrent radiotherapy and chemotherapy and immunomaintenance therapy | Department of Otolaryngology head and Neck Surgery, The Sixth Medical Center, PLA General Hospital; Chinese PLA General Hospital, Shanghai Junshi Biomedical Technology Co., LTD | hypopharyngeal cancer | | | | |
InTRist, NCT05888402: Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC |
|
|
| Recruiting | 2 | 50 | RoW | Toripalimab, Tuo Yi, Concurrent chemoradiation therapy and consolidation immunotherapy, The PACIFIC regimen | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Junshi Bioscience Co., Ltd. | Local Advanced Non-small Cell Lung Cancer | 06/25 | 12/25 | | |
NCT05891080: Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial |
|
|
| Not yet recruiting | 2 | 124 | NA | Toripalimab, JS004, Pemetrexed, Nab-paclitaxel, Carboplatin, Surgery | Shanghai Pulmonary Hospital, Shanghai, China | Stage III Non-small Cell Lung Cancer | 07/25 | 07/30 | | |
NCT06093438: Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Toripalimab | Tianjin Medical University Cancer Institute and Hospital | Cervical Cancer, Induction Chemotherapy, Immunotherapy | 07/25 | 07/26 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
NCT05461235: Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma |
|
|
| Not yet recruiting | 2 | 1 | NA | Pembrolizumab, Keytruda, Nivolumab, Opdivo, Sintilimab, Daboshu, Toripalimab, Tuoyi, Camrelizumab, Airuika, Tislelizumab, Baizean, NK-Cell or DC-Cell | China Medical University, China | PD-1 Antibody, DC-Cell, NK-Cell, Gastrointestinal Tumours | 07/25 | 12/25 | | |
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 246 | RoW | Axitinib plus Toripalimab, nephrectomy | ZHOU FANGJIAN, Pfizer | Renal Cell Carcinoma, Neoadjuvant | 07/25 | 03/26 | | |
TA7, NCT06020755: Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7 |
|
|
| Not yet recruiting | 2 | 17 | RoW | Toripalimab, Actinomycin-D | Peking Union Medical College Hospital, Obstetrics & Gynecology Hospital of Fudan University, Shengjing Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Henan Cancer Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Dalian Maternity and Child Care Hospital, The First Affiliated Hospital of Xiamen University, Sichuan Cancer Hospital & Institute, Shanghai Junshi Bioscience Co., Ltd. | Gestational Trophoblastic Neoplasia | 08/25 | 08/25 | | |
ChiCTR2200066334: Toripalimab and Lenvatinib combined with SBRT and HAIC for HCC With Portal Vein Invasion：A single-arm, single-center clinical study |
|
|
| Not yet recruiting | 2 | 20 | China | Toripalimab and lenvatinib combined with SBRT and continuous hepatic arterial infusion | The Second Affiliated Hospital of Hainan Medical College ; The Second Affiliated Hospital of Hainan Medical College, self-financing | HCC | | | | |
NCT06062485: Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | NA | Surufatinib+Toripalimab+AG | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Ampullary Carcinoma | 10/25 | 10/26 | | |
ChiCTR2200066336: Phase II clinical study of immunocheckpoint inhibitors combined with concurrent chemoradiotherapy in high-risk or ctDNA positive head and neck squamous cell carcinoma |
|
|
| Not yet recruiting | 2 | 30 | China | Toripalimab | the First Hospital of China Medical University ; the First Hospital of China Medical University, Subject self-raised | head and neck squamous cell carcinoma | | | | |
NCT04624308: Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC |
|
|
| Not yet recruiting | 2 | 81 | RoW | Toripalimab, Tuoyi | Sun Yan, Shanghai Junshi Bioscience Co., Ltd. | Hypopharyngeal Neoplasm Malignant Primary | 10/25 | 12/25 | | |
NCT05048017: Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 20 | RoW | Regorafenib, BAY 73-4506, Stivarga, PD-1 inhibitor, Camrelizumab (AiRuiKa™)、Toripalimab、Pembrolizumab(Keytruda) | Peking Union Medical College Hospital | Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor | 11/25 | 12/25 | | |
NCT06124963: A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations |
|
|
| Recruiting | 2 | 20 | RoW | WX390, WXFL10030390, Toripalimab | Shanghai Jiatan Pharmatech Co., Ltd | Gastric Type Adenocarcinoma (GAS) With STK11 Mutation | 12/25 | 12/25 | | |
PC-1, NCT05993858: Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC |
|
|
| Not yet recruiting | 2 | 33 | RoW | 3cycles (Toripalimab + cetuximab), Surgery, Radiotherapy or chemoradiotherapy | Wuhan Union Hospital, China | Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | 12/25 | 12/26 | | |
NCT06105008: Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer |
|
|
| Not yet recruiting | 2 | 80 | RoW | Disitamab Vedotin, RC48-ADC, DV, Toripalimab, JS001 | RemeGen Co., Ltd. | Breast Neoplasms | 12/25 | 04/26 | | |
NCT06111274: A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 82 | RoW | Pimicotinib (ABSK021), Gemcitabine, nab-Pacilitaxel, Toripalimab | Abbisko Therapeutics Co, Ltd | Advanced Pancreatic Cancer | 12/25 | 12/26 | | |